^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR G719X

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    13d
    TARGET: A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (clinicaltrials.gov)
    P2, N=187, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib)
    28d
    Proteogenomic analysis of air-pollution-associated lung cancer reveals prevention and therapeutic opportunities. (PubMed, Elife)
    Finally, MAD1 and TPRN were identified as novel potential therapeutic targets in XWLC. Our study provides a valuable resource for researchers and clinicians to explore prevention and treatment strategies for air-pollution-associated lung cancers.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719X
    1m
    ORBITAL: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, Intergroupe Francophone de Cancerologie Thoracique | Trial completion date: Feb 2024 --> Dec 2024
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib)
    1m
    Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    2ms
    A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells. (PubMed, Sci Rep)
    Studies have shown that afatinib is beneficial for NSCLC patients with rare EGFR mutations...The results showed that WZ3146 induced cytotoxic effects, inhibited growth vitality and proliferation via ERK and AKT pathway in the EGFR G719X mutant cells. Our findings suggest that WZ3146 may be a promising treatment option for NSCLC patients with the EGFR exon 18 substitution mutation G719X.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719X • EGFR G719A • EGFR G719S • EGFR exon 18 mutation • EGFR G719C
    |
    Gilotrif (afatinib)
    2ms
    NCI-2021-04325: Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2ms
    Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC (clinicaltrials.gov)
    P1, N=52, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jun 2024
    Trial completion • Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q
    |
    Tagrisso (osimertinib) • simvastatin
    4ms
    Comparison Between EGFR PCR Alone and NGS with Gene Fusion PCR for Detecting Oncogenic Driver Alteration in Thai NSCLC Patients (IASLC-WCLC 2024)
    However, NGS had a 12-day longer TAT compared to EGFR PCR. Gene fusion-panel PCR and NGS identified an additional 11.6% of patients harboring actionable alterations who may benefit from FDA-approved targeted therapies.
    Clinical • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • EGFR G719X • KRAS G12 • EGFR positive • EGFR L747P • EGFR L861R
    |
    cobas® EGFR Mutation Test v2 • Idylla™ GeneFusion Assay • Idylla™ BRAF Mutation Test • Idylla™ EGFR Mutation Test
    6ms
    From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer. (PubMed, Clin Cancer Res)
    While afatinib, a second-generation EGFR-TKI, has received FDA approval for patients with these uncommon EGFR mutations, the approval was based on a post-hoc analysis of randomized clinical trials. By synthesizing these findings, we aim to guide oncologists towards more informed decisions in employing TKIs for NSCLC with uncommon EGFR mutations other than exon 20 insertion. Additionally, we explore potential treatment strategies tailored to these patient populations to address the challenges posed by these mutations.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR exon 18 mutation
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)
    6ms
    EXCLAIM-2: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (clinicaltrials.gov)
    P3, N=354, Active, not recruiting, Takeda | Trial completion date: Jun 2026 --> Dec 2024 | Trial primary completion date: Feb 2026 --> Dec 2024
    Trial completion date • Trial primary completion date • EGFR exon 20
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    cisplatin • carboplatin • pemetrexed • Exkivity (mobocertinib)
    6ms
    U31402-A-U102: HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=309, Recruiting, Daiichi Sankyo | Active, not recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jan 2022 --> Mar 2026
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • ALK-ROS1 fusion
    |
    patritumab deruxtecan (U3-1402)
    6ms
    Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam. (PubMed, Ther Adv Med Oncol)
    Afatinib is effective for locally advanced metastatic NSCLC with uncommon EGFR mutations. Patients with G719X, compound G719X-S768I mutations, and tolerated doses of 20 or 30 mg had a longer median TTF than those with other mutations.
    Clinical • Journal • Real-world evidence • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    |
    Gilotrif (afatinib)
    6ms
    Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18. (PubMed, Transl Lung Cancer Res)
    EGFR-TKIs showed great efficacy in terms of responses and survival in patients harboring exon 18 EGFR rare mutations. This may justify the use of targeted therapies as a potential treatment strategy for these patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719X • EGFR exon 18 mutation • EGFR G724S
    7ms
    TREBLE: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=8, Terminated, EQRx International, Inc. | Phase classification: P3b --> P3
    Phase classification • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Ameile (aumolertinib)
    7ms
    Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC (clinicaltrials.gov)
    P2, N=23, Not yet recruiting, Taipei Veterans General Hospital, Taiwan | Trial completion date: May 2025 --> Jun 2027 | Trial primary completion date: May 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • pemetrexed
    7ms
    ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • pemetrexed
    7ms
    OCEANiC: A Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients WithnStage IIA-IIIA EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection (ACTRN12623000552684)
    P2, N=100, Recruiting, The University of Sydney | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib)
    8ms
    Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review. (PubMed, J Thorac Oncol)
    This systematic review supports the use of 2nd generation TKI afatinib for G719X, S768I, E709X and L747X mutations, as well as for compound uncommon mutations. For other uncommon mutations such as L861Q, 3rd generation TKI, such as osimertinib, could also be considered, given its activity and toxicity profile.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)
    9ms
    Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201. (PubMed, Lung Cancer)
    This analysis demonstrated long-term clinical benefit with lazertinib 240 mg in patients with EGFR-mutated NSCLC who had not previously received EGFR TKIs. The safety profile for lazertinib was tolerable and consistent with that previously reported.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR G719X
    |
    Lazcluze (lazertinib)
    9ms
    ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • pemetrexed
    9ms
    Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC (clinicaltrials.gov)
    P1, N=52, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q
    |
    Tagrisso (osimertinib)
    9ms
    Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR positive • EGFR exon 19 deletion + EGFR L861Q
    |
    Tagrisso (osimertinib) • navitoclax (ABT 263)
    10ms
    Current management of uncommon EGFR mutations in non-small cell lung cancer. (PubMed, Curr Probl Cancer)
    It is crucial to understand these distinct variants and their specific responses to active treatment options to optimize care. In this review, we discuss these uncommon mutations in depth and dissect the current literature regarding their treatment outcomes and subsequent evidence-based management guidelines.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation
    10ms
    A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=34, Completed, Zeno Pharmaceuticals, Inc. | Phase classification: P1/2 --> P1
    Phase classification • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    ZN-e4
    10ms
    An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=59, Active, not recruiting, Incyte Corporation | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q
    |
    Tagrisso (osimertinib) • itacitinib (INCB039110)
    10ms
    AURA: AZD9291 First Time In Patients Ascending Dose Study (clinicaltrials.gov)
    P1/2, N=603, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q
    |
    Tagrisso (osimertinib)
    11ms
    Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Black Diamond Therapeutics, Inc. | Phase classification: P1 --> P1/2 | N=120 --> 200
    Phase classification • Enrollment change
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR C797S • EGFR G719X
    |
    Tagrisso (osimertinib) • BDTX-1535
    11ms
    FURMO-002: Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (clinicaltrials.gov)
    P1, N=170, Recruiting, ArriVent BioPharma, Inc.
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M
    |
    Ivesa (firmonertinib)
    11ms
    Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • NOTCH3 (Notch Receptor 3)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)
    11ms
    Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective. (PubMed, Pathol Res Pract)
    This is one of the largest cohorts of NSCLC for comprehensive targeted mutational profiling and correlation with the PD-L1 expression. The mutations are more prevalent in non-smoker females for all genes, except ALK (non-smoker males). MET and BRAF mutations are more common in elderly population whereas EGFR mutations, and ALK and ROS1 genes rearrangements are more prevalent in younger population. The most common histopathologic subtype/feature associated with various mutations was as follows: acinar with EGFR, solid with ALK, macronucleoli with ROS1, signet ring with MET, and micropapillary with BRAF.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • MET exon 14 mutation • PD-L1 negative • EGFR L861Q • ALK mutation • ROS1 rearrangement • EGFR G719X • MET mutation • EGFR S768I
    11ms
    Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations. (PubMed, Curr Treat Options Oncol)
    Dacomitinib may also be an option for these mutations given similar efficacy to afatinib. Superior CNS penetrance and well managed toxicity profile may also be reasons to consider osimertinib. Given that the choice of TKI may depend on the specific mutation, it is crucial that every patient diagnosed with NSCLC undergo comprehensive sequencing to identify these mutations.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • Vizimpro (dacomitinib)
    11ms
    AURA2: Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (clinicaltrials.gov)
    P2, N=210, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q
    |
    Tagrisso (osimertinib)
    12ms
    Balise: A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q
    |
    erlotinib • emibetuzumab (LY2875358)
    12ms
    NCI-2021-04325: Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=55 --> 35
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    12ms
    Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X + S768I mutations in non-small cell lung cancer: An in silico approaches. (PubMed, Open Life Sci)
    The present study may be helpful in the development of new EGFR-targeted drugs based on the structure of rare mutations. Our findings may aid in developing new targeted treatments for patients with EGFR S768I and EGFR G719X + S768I mutations.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR wild-type • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I • EGFR G719C
    12ms
    RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC (clinicaltrials.gov)
    P1/2, N=106, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation
    |
    Loqtorzi (toripalimab-tpzi) • Ivesa (firmonertinib) • RC108
    12ms
    FURMO-002: Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (clinicaltrials.gov)
    P1, N=170, Recruiting, ArriVent BioPharma, Inc. | Phase classification: P1b --> P1
    Phase classification • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M
    |
    Ivesa (firmonertinib)
    12ms
    Prognostic Outcomes and Recurrence Patterns in Resected Stage I Lung Adenocarcinoma Harboring Atypical Epidermal Growth Factor Receptor Mutation. (PubMed, Eur J Cardiothorac Surg)
    Exon20 insertion mutation was correlated with favorable DFS and lower incidence of bone metastasis in radiological solid lung adenocarcinoma harboring atypical EGFR mutation.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I
    12ms
    First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial. (PubMed, JAMA Oncol)
    The results support the use of osimertinib as a treatment option for this patient population. Japan Registry of Clinical Trials Identifier: jRCTs071200002.
    Clinical • P2 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib)
    1year
    TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection. (PubMed, Clin Lung Cancer)
    Exploratory endpoints include: tissue/plasma concordance; analysis of circulating molecules in plasma samples using different profiling approaches to detect minimal residual disease; incidence and change over time of incidental pulmonary nodules. TARGET is currently recruiting, and completion is expected in 2029.
    P2 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib)
    1year
    ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial primary completion date: Sep 2023 --> Dec 2023
    Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • pemetrexed